Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$101.88 USD

101.88
10,180,742

-0.44 (-0.43%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection

The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.

Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know

Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs

FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis

AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.

Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know

Merck (MRK) closed at $127.99 in the latest trading session, marking a +0.38% move from the prior day.

Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.

AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate

AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

In the closing of the recent trading day, Merck (MRK) stood at $130.20, denoting a -1.24% change from the preceding trading day.

Mark Vickery headshot

Top Analyst Reports for Microsoft, Apple & Alphabet

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Apple Inc. (AAPL) and Alphabet Inc. (GOOGL), as well as a micro-cap stock CompX International Inc. (CIX).

Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.

Merck (MRK) Stock Moves 0.27%: What You Should Know

The latest trading day saw Merck (MRK) settling at $131.84, representing a +0.27% change from its previous close.

AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal

Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.

Merck (MRK) Ascends But Remains Behind Market: Some Facts to Note

The latest trading day saw Merck (MRK) settling at $129.45, representing a +0.57% change from its previous close.

Company News for June 4, 2024

Companies In The Article Are:NVDA, MRK,MRNA, SPOT, SRCL and WM

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More

J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

Style Box ETF report for SCHD

Merck (MRK) to Buy Private Ophthalmology Company EyeBio

Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

Why Merck (MRK) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore

This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.

Here's Why Merck (MRK) Stock Has Outperformed Industry YTD

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.

The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: American Express, Walmart, Amazon, The Goldman Sachs and Merck & Co

American Express, Walmart, Amazon, The Goldman Sachs and Merck & Co are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates

Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.